GSK Positions Blenrep for Market Revival with 42% Survival Benefit in Multiple Myeloma

GSK is making a strategic comeback with Blenrep, targeting a resurgence in the market for relapsed or refractory multiple myeloma treatment. The company highlights a 42% reduction in death risk compared to J&J's Darzalex, achieved through a combination of Blenrep, bortezomib, and dexamethasone, following data from the Phase III DREAMM-7 study[1][2]. This combination has demonstrated not only a substantial improvement in overall survival projections—84 months versus 51 months for Darzalex—but also better secondary outcomes like longer progression-free survival and response duration[1]. GSK is also addressing prior challenges by modifying dosing practices to counteract ocular toxicity concerns and plans to further affirm Blenrep's efficacy with a new phase 3 trial in first-line treatment settings[2].